key: cord-0929302-u79x6h4x
authors: Lang, Claudia Cécile Valérie; Schmid-Grendelmeier, Peter; Maverakis, Emanual; Brüggen, Marie-Charlotte
title: Reply to “Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era”
date: 2021-07-15
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.06.048
sha: 23ddd2ac5cb41dd993a400a6b244f392c1184eac
doc_id: 929302
cord_uid: u79x6h4x

nan

Reply to ''Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era''

To The Editor:

It is exciting to see that IL-5 receptor alpha (IL-5Ra) blockade (benralizumab) is gaining interest as a therapy for drug rash with eosinophilia and systemic symptoms (DRESS) in the setting of severe acute respiratory syndrome coronavirus 2 infection. In the most recent report by Mesli et al 1 and our previous article, 2 patients with severe acute respiratory syndrome coronavirus 2 infection had severe corticosteroid-refractory presentations of DRESS that rapidly responded to benralizumab. These observations raise intriguing questions.

First, whether and how does a severe coronavirus disease 2019 (COVID-19) course interfere with or favor DRESS development. On the one hand, it is conceivable that, as indicated by our own experimental work on COVID-19-related maculopapular drug rashes, 3 the systemic cytokine storm associated with severe COVID-19 favors hyperactivation of T cells, which in turn may predispose patients to delayed drug hypersensitivity reactions. On the other hand, DRESS onset may also precede/induce viral reactivation. The latter hypothesis is supported by (a) the virus detected in bronchial aspirates of Mesli et al's patient 48 hours after intensive care unit admission and (b) our knowledge about the occurrence of viral reactivation (eg, Human Herpes Virus 6 and Epstein-Barr Virus) in DRESS. 4 The second important question concerns the therapeutic potential of the IL-5 axis interference in DRESS beyond the setting of COVID-19. To this end, we can now report here the treatment of 3 non-COVID-19-related patients with DRESS with anti-IL-5Ra antibody ( Table I) . All of them fulfilled the RegiSCAR diagnostic criteria for severe DRESS 5 and had not adequately responded to systemic high-dose glucocorticoids (GCSs). Two patients showed a rapid and complete clinical recovery (defined as regression of cutaneous/systemic symptoms and eosinophilia) from DRESS following a single administration of benralizumab and concurrent tapering of low-dose GCSs. The third patient had a long relapsing course of DRESS before starting benralizumab and developed a clinical relapse and eosinophilia 4 months after the injection. We therefore decided to treat her with mepolizumab every 4 weeks (so far administered twice), and she became and has remained symptom-free.

These additional findings argue in favor of IL-5 axis blockade as a broader therapeutic option in DRESS, possibly associated with less adverse effects when compared with GCSs and other ''classical'' systemic immunosuppressants. To further implement this therapeutic approach in DRESS, several aspects need to be addressed: do only certain subgroups of patients benefit from IL-5 axis blockade (eg, patients with severe DRESS or those with evidence of viral reactivation); will IL-5 blockade have similar efficacy to targeting IL-5Ra or should a combination be considered; do patients require single or multiple administrations of the drug; and should patients receive coadministration of GCSs or topical corticosteroids?

Taken together, there remains a great need for prospective studies of therapeutic agents interfering with the IL-5 axis in DRESS and investigations exploring the pathomechanisms underlying DRESS within or unrelated to COVID-19.

Benralizumab: a tailored treatment for life-threatening DRESS in the COVID-19 era?

Benralizumab for severe DRESS in two COVID-19 patients

Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients

Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system

Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?